



“Designing Bitopic Molecules for the Treatment of Substance Use Disorders”

Highly selective dopamine D3 receptor (D3R) partial agonists/antagonists have been developed for the treatment of substance use disorders (SUD) using a bitopic drug design. Recently, we have used our bitopic and selective D3R agonist to determine the cryo-EM structure of the hD3R coupled to a G α heterotrimer. Tweaking the selectivity and efficacy of these compounds has broadened their potential therapeutic efficacy toward neuropsychiatric disorders comorbid with SUD.

Amy Newman, Ph.D.

Office of the Scientific Director
National Institutes of Health
National Institute on Drug Abuse-Intramural
Research Program

Host: Prashant Donthamsetti

November 2nd, 2023
3:00 PM
512 Light Hall

Co-Sponsored by:



Vanderbilt Center for
Addiction Research
Discovering new roads to recovery